220
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Glibenclamide nanosuspension inhaler: development, in vitro and in vivo assessment

, , &
Pages 762-774 | Received 25 Aug 2019, Accepted 03 Apr 2020, Published online: 20 Apr 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Dipti Srivastava, Zeeshan Fatima, Chanchal Deep Kaur, Anjali Mishra, Sanap Sachin Nashik, Dilshad A. Rizvi & Rammani Prasad. (2022) Glibenclamide–malonic acid cocrystal with an enhanced solubility and bioavailability. Drug Development and Industrial Pharmacy 48:8, pages 417-424.
Read now
Biswadip Sinha, Rainer H. Müller & Jan P. Möschwitzer. (2021) Can the cavi-precipitation process be exploited to generate smaller size drug nanocrystal?. Drug Development and Industrial Pharmacy 47:2, pages 235-245.
Read now

Articles from other publishers (4)

Amar Abderrahmani, Sabine Szunerits, Stephane Dalle & Rabah Boukherroub. 2022. Nanotechnology for Diabetes Management. Nanotechnology for Diabetes Management 92 112 .
Jian Guan, Huiya Yuan, Shihui Yu, Shirui Mao & Qi Tony Zhou. (2022) Spray dried inhalable ivacaftor co-amorphous microparticle formulations with leucine achieved enhanced in vitro dissolution and superior aerosol performance. International Journal of Pharmaceutics 622, pages 121859.
Crossref
Mary B. McGuckin, Jiawen Wang, Rand Ghanma, Nuoya Qin, Santiago D. Palma, Ryan F. Donnelly & Alejandro J. Paredes. (2022) Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes. Journal of Controlled Release 345, pages 334-353.
Crossref
Shihui Yu, Xiaohui Pu, Maizbha Uddin Ahmed, Heidi H. Yu, Tarun Tejasvi Mutukuri, Jian Li & Qi Tony Zhou. (2021) Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa. International Journal of Pharmaceutics 610, pages 121160.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.